Mission Statment
InnaVirVax is a privately-owned biopharmaceutical company dedicated to the development of a cutting edge discovery in the field of therapy/prevention and prognostic of AIDS and HIV infection, other infectious diseases, and new cancer therapies.

Company Mission
InnaVirVax is developing product candidates resulting from a beakthrough discovery. Based on a new paradigm (i.e. the understanding of the mechanism responsible for the decline of the CD4+ T lymphocytes in HIV-infected patients), the products currently developed by InnaVirVax will allow the prevention and the treatment of AIDS in HIV-infected patients. Moreover, InnaVirVax has an AIDS prognostic test in its R&D portfolio.  
Lastly, InnaVirVax is developing an innovative cancer biotherapy relying on a totally new tumor surface antigen.
InnaVirVax product portfolio originates from Inserm, the French Medical research council, the AP-HP, the largest hospital in Europe, and University Pierre et Marie Curie in Paris.

Proprietary technology  

The discovery made by two founders of InnaVirVax has identified that a dysregulation of the innate immune system is responsible for the loss of CD4+ T lymphocytes in HIV-infected patients. The understanding of this dysregulation (resulting in the presence at the surface of the CD4+ T  lymphocytes of a NK cell ligand, making CD4+ T lymphoyctes sensitive to NK-mediated cell lysis) has allowed InnaVirVax and its academic partners to design a therapeutic vaccine for HIV infection that has been successfully tested in non human primates. The knowledge of the above described mechanism has also enabled InnaVirVax to develop a prognostic test for the onset of AIDS in asymptomatic HIV-infected patients.
In addition InnaVirVax is developing an innovative cancer therapy based on a new tumor cell surface antigen.

 

Intellectual Property
The products developed by InnaVirVax are covered by two patent families among which are WO 2004/070385 and WO 2005/076001. InnaVirVax is actively consolidating its intellectual property portfolio. InnaVirVax has filed two patent applications in 2011.

Alliances
InnaVirVax is seeking for industrial alliances with corporate partners able to further develop and commercialize InnaVirVax product candidates.